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Abstract 8 
The Johannesburg Cancer Study (JCS) aims were to examine whether cancer risk factors 9 
identified in Western countries applied to black patients in Johannesburg, South Africa and to 10 
understand the impact of HIV on cancer risk, with a view to identifying previously 11 
unrecognised HIV associated cancers. 12 
A total of 24 971 black patients with an incident histologically proven (>95%) cancer of any 13 
type were enrolled between 1995-2016. Response rates were >90%. Patients provided 14 
informed consent, lifestyle and demographic information using a structured questionnaire; 15 
19 351 provided a serum sample and 18 972 a whole blood sample for genomic analyses. This 16 
is currently the largest cancer epidemiological biobank in Africa. JCS uses a cancer case-17 
control method; controls being cancer types unrelated to exposures of interest. 18 
Published results show the importance of HIV in several cancers known to be infection 19 
associated e.g. Kaposi sarcoma (OR=1683;CI=595-5194) in those with high Kaposi-sarcoma-20 
associated-herpesvirus titres; no effect of HIV on lung or liver cancer-in the latter showing a 21 
strong association with HBVDNA, sAg and c positivity (OR=47;CI=21-104). Comparable data to 22 
higher-income country studies include lung cancer ORs in relation to smoking (15+g 23 
tobacco/day) (ORMales=37;CI=21-67, ORFemales=18.5;CI=8-45) and associations between alcohol 24 
and oesophageal cancer in smokers (ORM&F=4.4;CI=3-6). Relationship between hormonal 25 
contraception declined to null 10 or more years after stopping for breast (OR=1.1;CI=0.9-1.4) 26 
and cervical cancer (OR1.0;CI=0.8-1.2), and protective effects shown, five or more years after 27 
stopping for ovarian (OR=0.6;CI=0.4-1) and endometrial cancer (OR=0.4;CI=0.2-0.9). 28 
Preferential access is based on data requests promoting data pooling, equal collaborative 29 
opportunities and enhancement of research capacity in South Africa. 30 
The JCS is a practical and valid design in otherwise logistically difficult settings. 31 
 32 
Background 33 
South Africa (SA) has an increasingly high burden of cancer, especially among adults,1 as 34 
leading drivers of carcinogenesis (HIV, smoking, alcohol, reproductive patterns) change in 35 
prevalence over time.2–5 In response to the growing burden of cancer, the Johannesburg 36 
Cancer Study (JCS) was established in 1995 at the National Cancer Registry of SA (NCR). Its 37 
original aims were to examine whether risk factors identified for cancer in Western countries 38 
3 
applied to black patients in Johannesburg, SA, and to understand the impact of HIV on cancer 1 
risk, with a view to identifying previously unrecognised HIV associated cancers. Similar 2 
protocols were also used in two other studies. The first, in 1991, was based in Rwanda and 3 
was lost with the genocide of 1994.6 The second was in Uganda, which recruited patients 4 
between 1994-1998.6,7 The JCS aims evolved into measuring the relative importance of known 5 
and emerging risk factors for cancer in a local setting and establishing a biobank for ongoing 6 
investigations of infectious and genetic drivers of cancer. This is the largest cancer 7 
epidemiological study on the continent, with just under 25 000 African cancer patients, 8 
providing lifestyle information and blood samples (for serum and DNA). 9 
The JCS was preceded by a medical record review / pilot study between 1992 and 1995 on 10 
the association between HIV and cancer among cancer patients attending medical oncology 11 
departments of the Charlotte Maxeke Johannesburg Academic Hospital (CMJAH), and its 12 
affiliated Radiation Oncology ward of Hillbrow Hospital (ROH).8 The pilot study demonstrated 13 
the feasibility of consecutive patient data collection in local public (oncology) healthcare 14 
facilities. 15 
The JCS was launched in 1995 with recruitment commencing using a structured two-page 16 
questionnaire at the two sites mentioned above and the haematology and medical wards of 17 
Chris Hani Baragwanath Academic Hospital (CHBAH). CHBAH refers most cancer patients 18 
eligible for radiation therapy and medical oncology to ROH or CMJAH so recruitment at 19 
CHBAH was terminated in 2001. ROH relocated to CMJAH in 2005 and patient recruitment at 20 
the CMJAH was terminated in April 2016. Patients undergoing cancer treatment generally 21 
require pathological confirmation of their cancer diagnosis, hence the proportion of cancer 22 
cases verified histologically was >95% (Table 1), substantially higher than in similar studies in 23 
Uganda and Rwanda.7 24 
Recruitment took place in a consecutive manner at the medical oncology or radiation therapy 25 
ward waiting rooms. Eligible patients were identified through clinic daily logbooks, 26 
approached by trained research oncology nurses and invited to participate in the JCS. 27 
Participants provided signed informed consent or witnessed oral consent. Cancer counselling 28 
was available to participants by our oncology research nurses. All interviews were done in 29 
private rooms in the preferred language of the patient, mainly Zulu, Sotho, related dialects or 30 
English. 31 
Inclusion /Exclusion Criteria /Case definition 32 
Incident cancer patients self-identified as black African, aged 18 and older, able to provide 33 
informed consent to participate, able to speak one of the main languages in SA and optionally 34 
able to provide two blood samples were included in the study. Persons with treatment naïve, 35 
incident cancer were identified by reviewing medical records and preliminary patient 36 
discussions. Diagnosis of primary site of cancer and morphology were determined by review 37 
of medical records and pathology results of the tumour biopsies. Self-identified non-resident 38 
South African patients were excluded. 39 
 40 
4 
Data collected 1 
Demographic data collection 2 
The JCS collected diagnostic, lifestyle and demographic information using a two-page 3 
questionnaire. These included tumour topography of primary site and morphology (from 4 
medical records), lifestyle and demographic questions, date of birth and interview, place of 5 
birth and current residence, highest educational attainment, type of fuel used for heating and 6 
cooking, smoking (current, former and never, dates started and stopped, types and amounts 7 
smoked), snuff use (never, past, current), alcohol status (initially type of alcohol and 8 
frequency consumed, later changed to type, frequency and amount consumed), history of 9 
self-reported high blood pressure and diabetes, occupation (type of work and industry), 10 
number of sexual partners, and main language of mother and father. For women, separate 11 
questions included age at first and last child, number of live children and miscarriages, and 12 
frequency and type of hormonal contraception used (oral or injectable). In 2004 questions on 13 
knowledge about antiretrovirals (ARV) and HIV status were added. 14 
Questionnaires and pathology reports were returned to the NCR for dual data capture and 15 
data quality control. Cancer topography and morphology was coded by NCR trained 16 
nosologists using ICDO-3 and into diagnostic categories using IARC ICDO-3 to ICD-10 17 
conversion rules. 18 
Blood sample collection 19 
Venous blood samples were collected from participants starting in 1996 in a BD vacutainer® 20 
serum separation tube. This was processed, usually within 24 hours by centrifuging at 1000-21 
2000g for 10 min in a refrigerated centrifuge and dividing the serum into ~4 aliquots in NUNC 22 
cryotubes and initially stored at -25°C. Serum was moved into -80°C freezers in 2011. The 23 
serum collected were of adequate quality and quantity for serological screenings of specific 24 
antibodies against multiple pathogens of carcinogenic risk to humans outlined by the IARC 25 
Monographs Volume 100B (such as HIV, KSHV, HPV).9-12 26 
Participants were asked by the study interviewers if they wished to have an HIV test 27 
performed, with results returned to them. If affirmative, interviewers drew a separate (non-28 
study) blood sample for testing using the pathology laboratory’s routine system. Interviewers 29 
were also trained in pre- and post-HIV counselling and report-back was discussed with the 30 
patient during their next appointment and results incorporated as part of their routine care. 31 
Blood collection for DNA isolation commenced in 1997 in one BD® 4ml EDTA vacutainer. 32 
Vacutainers were stored in -30°C for future DNA isolation. We demonstrated recently that 33 
whole blood samples stored (between 2-19 years) at -30°C yielded sufficient DNA with 34 
adequate quality for downstream genetic analysis such as genotyping genetic variants on 35 
multiple platforms and DNA sequencing.13,14 36 
Study recruitment continued at ~1100 cases per annum. At the end of recruitment in 2016, 37 
24 971 patients were enrolled, 19 351 had a serum sample and 18 972 had a whole blood 38 
sample collected. Between 1998-2001 we also recruited 1173 patients presenting with 39 
cardiovascular diseases as a cancer-negative control group. 40 
5 
Ethics 1 
The JCS has University of the Witwatersrand (Wits) Human Research Ethics Committee 2 
(Medical) (HREC) clearance (M981119, M040445, M090361, M140271, M1606103, 3 
M120117). Participants provided witnessed consent to a once-off interview and optional 4 
blood draw and to have their information and samples stored anonymously for any future 5 
infection or inherited risk factor investigations for cancer, with the understanding that no 6 
research would be done without the approval of the Wits HREC as well as the applicable HREC 7 
at host institutions. 8 
 9 
Data Resource Use: 10 
Study design: 11 
The study design we used to perform several analyses is akin to a hospital-based case-control 12 
study. For each study (hypothesis) controls were selected on a case-by-case basis by first 13 
defining the appropriate cases and then choosing sex and age range matched participants 14 
with cancers unrelated to the main exposures of interest under investigation (see illustration 15 
in Table 3). So, for example, in a study on the effects of smoking on lung cancer we excluded 16 
all those participants with cancers that were suspected or known to be associated with 17 
smoking.15 We identified these by reviewing IARC Monographs on Carcinogenicity in the first 18 
instance, and if these were out of date we referred to informative reviews such Schottenfeld 19 
and Fraumeni’s textbook on cancer epidemiology (3rd and 4th editions), and by literature 20 
searches to identify other influential emerging studies. This has proven to be practical solution 21 
under an otherwise logistically difficult setting. The analyses used for selected lifestyle and 22 
serological data comprised calculations of case-control odds ratios adjusting for various 23 
known confounders. 24 
A choice of similarly-ill cancer controls, compared to the cases under investigation has the 25 
advantage of minimising referral bias (assuming all cancers are referred through similar 26 
pathways and catchment areas), interviewer bias (interviewers were never sure which 27 
hypothesis is being tested at any time) and recall bias (participants are both similarly sick, 28 
reducing potential recall biases of prior exposures between sick vs. healthy individuals). We 29 
minimised obvious biases by performing sensitivity analyses in which we removed each main 30 
cancer type from the pool of controls and recalculated odds ratios using the remaining 31 
controls,16 or by calculating the heterogeneity of exposure prevalences by cancer type among 32 
controls.9 We interviewed 1173 patients with cardiovascular disease which served as an 33 
additional negative control group (in the case of an HIV and cancer study where no association 34 
between immune suppression and cardiovascular disease was suspected),10 and as an 35 
additional (positive) case group, when investigating smoking related cancers.15 36 
Evolution of risk factors: 37 
Table 1 illustrates the changes in prevalence of some of the key exposures in two periods over 38 
the 21-year life-course of this study, 1995-2004 and 2005-2016. For certain exposures such 39 
as tobacco smoking, alcohol consumption, hormonal risk factors and HIV seropositivity, the 40 
6 
prevalence was estimated by excluding cancers with known risk indications for the specific 1 
exposures to reduce sampling biases. 2 
One of the most important changes in exposures has been HIV seropositivity in cancers 3 
unrelated to known infectious agents, from 6.6% (in men) and 8.8% (in women) in the first 4 
period to 15.4% and 21.6%, respectively in the second period. This increase in the background 5 
HIV prevalence had a profound effect on the distribution of cancer in this population, with 6 
Kaposi sarcoma ranking first in men and third in women (previously ranked fifth in men and 7 
eighth in women). 8 
Smoking prevalence in men and women remained about the same but the median number of 9 
cigarettes dropped slightly. Alcohol consumption has decreased in women over the two 10 
periods. The use of coal and anthracite as fuel sources decreased, while the prevalence of 11 
electricity use increased, in keeping with government initiatives to electrify Soweto 12 
(Johannesburg’s former satellite township) and other formerly black and under-invested 13 
areas. 14 
Table 1 also shows the evolution of the top three cancer types changing in men, in order, from 15 
oesophagus, prostate and lung in 1995-2006 to Kaposi Sarcoma, oropharyngeal and lung in 16 
2005-2016. Changes in cancer relative frequency were also observed in women, with cervix, 17 
breast and oesophageal cancer being the top three cancers in 1995-2004 to breast, cervix and 18 
Kaposi Sarcoma in 2005-2016. Similar increases in rankings have been seen in the rarer 19 
infection related cancers such as the lymphomas, eye cancers and some genital cancers; these 20 
changes are also observed in the NCR national surveillance data.17 21 
[Insert table 1] 22 
Table 2 illustrates examples of the number of participants by cancer type and choice of 23 
potential controls in four scenarios, investigating smoking, alcohol, infection and hormonal 24 
contraception related cancers. 25 
[Insert table 2] 26 
Documentation of cancer risks in an urban African population: 27 
Table 3 summarises some of the main results from the JCS. The first paper from the study 28 
documented Kaposi Sarcoma odds ratios of 1 683 in those who were HIV infected and had 29 
high titres of Kaposi’s sarcoma-associated herpesvirus (KSHV), compared to about 12-fold 30 
risks in those who were not infected with HIV. This illustrates that against a background of 31 
KSHV the causal association between HIV and Kaposi Sarcoma, one of the first syndromes to 32 
be defined by the CDC as an AIDS related cancer.18 This important locally derived information 33 
was cited by the “Durban Declaration” 19 in response to South African government denial of 34 
the role HIV played in causing AIDS. 35 
The risk for hepatocellular carcinoma (HCC) increases significantly in the presence of hepatitis 36 
B viral infection and HIV co-infection, however the HIV alone does not appear to be a risk 37 
factor for HCC in the South African black population.11 This may be suggestive of impaired 38 
innate and adaptive immune response in HIV co-infection leads to an reduction of 39 
7 
inflammation related to immune-mediated clearance of HBV-infected hepatocytes.20,21 Thus, 1 
effective control of hepatitis B infection through the use of vaccines at infancy may be an 2 
effective method for reducing risk of HCC in a population burdened with HIV. 3 
The JCS has documented the local effects of some of the main drivers of cancer risk such as 4 
HIV infection, causing increases in AIDS-related (viz. Kaposi Sarcoma, cervix, lymphoma) and 5 
other infection related cancers, including an increased risk for squamous cell skin cancer but 6 
no increased risk in relation to hepatocellular and lung cancer.10 One peculiarity of these data 7 
was that the risks for e.g. Kaposi Sarcoma and HIV, were one or two orders of magnitude 8 
lower than what was found in Western countries (~20-50 vs. >1000). This was explained by 9 
the (endemic) background incidence of KS in (South) Africa being much higher than in 10 
developed countries.10 Other contributions include data to a 10-country collaboration 11 
showing a null effect of HPV on oesophageal cancer. 22 12 
The JCS also documented expected risks of smoking and lung cancer (and several other 13 
cancers) among heavy smoking black males (15g + tobacco per day) of ORs of about 24-37-14 
fold, which is similar to what was found in e.g. the British Doctors study of RR>16.9.23 Previous 15 
studies from Africa had very few people who were heavy smokers hence the higher risks in 16 
the JCS compared to other African studies and lower risks when compared to UK studies.24 In 17 
conjunction with smoking we documented the increased risks in relation to alcohol 18 
consumption in upper aerodigestive cancers, particularly among smokers.25 19 
In SA, the proportion of women using injectable contraceptives was three times higher than 20 
those using oral contraceptive pills.26 We showed that recent use of especially injectable 21 
hormonal contraception is associated with a modest increase in the risks of breast and 22 
cervical cancer, and reduced risks for ovarian cancer. Relationship between hormonal 23 
contraception declined to null 10 or more years after stopping for breast (OR=1.1;CI=0.9-1.4) 24 
and cervical cancer (OR1.0;CI=0.8-1.2), and protective effects shown, five or more years after 25 
stopping for ovarian (OR=0.6;CI=0.4-1) and endometrial cancer (OR=0.4;CI=0.2-0.9), in 26 
keeping with international studies.16,27 27 
[Insert table 3] 28 
Contribution to international and local collaborations: 29 
The JCS has enjoyed success with its international and local collaborations and training of 30 
students. Several South African Medicine interns, MSc and PhD students have used the data 31 
for a range of projects. The JCS has contributed data to the International Collaboration of 32 
Epidemiological studies on breast, endometrial and ovarian cancers,27,28 International 33 
Collaboration on cervical cancer29 and data and serum samples were pooled in an 34 
international study on HPV and oesophageal cancer (InterSCOPE Study).22 In recent years, JCS 35 
contributed DNA samples to the Men of African Descent and Carcinoma of the Prostate 36 
(MADCaP) consortium investigating the genetic and epidemiological risk for prostate cancer 37 
in resident African populations.30 DNA from cases of oesophageal squamous cell carcinoma 38 
was used to demonstrate association of genetic variants in the CHEK2 gene with this cancer.14 39 
Local collaborations included a study on hepatocellular carcinoma11, knowledge of HIV status 40 
at cancer diagnosis31 and versions of the questionnaire were used by colleagues in two other 41 
8 
local settings.32,33  Curent collaborations include an extensive assessment of genomic effects 1 
on prostate34, cervical, breast and oesophageal cancer, and the role of key lifestyles and 18 2 
infectious agents (‘onco-agents’, 10 known and eight suspected to increase cancer risk) in 3 
association with several cancer types.35 4 
 5 
Strengths: 6 
The successes of the JCS in a resource constrained environment can be attributed to a number 7 
of factors. The design of the questionnaire was simple, short and practical allowing for sick 8 
patients to be interviewed while awaiting consultation in radiation and medical oncology 9 
clinics. Highly trained research nurses administered the interviews which required minimal 10 
input from busy clinic staff. Patients found added value in participation as the interviewers 11 
provided counselling on their cancer diagnosis and the path that lay ahead for them. The 12 
study was conducted over many years, so the interviewers were integrated into the clinical 13 
team. This enhanced the clinical service offered through nurse interviewer-patient 14 
interaction, occasionally incorporating HIV pre- and post-test counselling. 15 
In places where there are tertiary hospitals with reasonably good cancer treatment and 16 
diagnostic facilities, and where cohort studies are impractical, the JCS offers a pragmatic 17 
methodology to obtain information on cancer risk factors in otherwise difficult study settings. 18 
In this way it was possible to obtain up-to-date information on the relative importance of key 19 
risk factors in a setting and develop local capacity in cancer epidemiology and genomics.  20 
Many of the current, relevant and common cancer risk factors were fitted into a 2-page 21 
questionnaire. It is possible to expand this questionnaire into three pages using31 a common 22 
set of questions and add a fourth page focusing on local risk factors,5 and (where practical) 23 
extend the recruitment to cancer-free spouses of cancer patients to obtain an additional non-24 
cancer control group.36 We did attempt interviewing spouses but this proved logistically 25 
difficult as many spouses lived too far away to visit their sick partners. 26 
JCS has recruited cancer patients with high histological verification rates in a continuous 27 
fashion over 20 years. A carefully annotated collection of biobanked samples with lifestyle 28 
data is now available. Response rates for the study have been excellent, over 90%.10 29 
Questionnaire completion rates were also high. Using cancer controls was a practical design 30 
which also minimizes most of the known case control study biases. Consistent questions were 31 
asked for most exposures over the course of the study allowing for historical comparisons. 32 
Reassuringly, the prevalence of key exposures in the controls studied resembles the 33 
background prevalence in the population. 34 
High quality DNA obtained from peripheral blood samples are usable for DNA sequencing 35 
studies to elucidate the prevalence of rare hereditary genetic risk factors (e.g. BRCA1 or 36 
BRCA2 for breast cancer) or genotyping of small numbers of candidate genes to genome-wide 37 
association studies (with appropriately matched external population-control data) to identify 38 
common genetic risk factors.13,14 39 
Limitations: 40 
9 
Given the retrospective nature of the study retrospective recall of past exposures limits which 1 
questions were asked. For this reason, dietary questions were avoided. Self-reporting of 2 
various pills and treatments can be problematic in low health literacy populations and may 3 
also be subject to some recall biases. Pre-cancer symptoms may have an effect on lifestyle 4 
behaviour, for example early symptoms of lung cancer e.g. coughing may cause some to stop 5 
smoking as a result of the illness. While we have controlled some of this by asking start and 6 
stop dates of smoking, this was not controlled for in several other questions (e.g. for snuff 7 
use) so some residual confounding by indication may still be possible. Of course, as new 8 
cancer – exposure associations are discovered post analysis, some control participants would 9 
then be deemed as wrongly classified. For example, colorectal cancer was only recently 10 
deduced to be associated with smoking, breast cancer with alcohol consumption37 and recent 11 
meta-analyses suggest a protective effect of alcohol on lymphoma (albeit in all cases the 12 
relative risks (RR) are relatively small).38 Such new evidence will inform future case control 13 
selection, but because each of these cancers is only a small fraction of all the cancer types 14 
comprising the control group, their overall influence on the odds ratios is minimised. 15 
Aside from providing interviewers to each clinic, this study was managed on a minimal budget, 16 
offered no administrative/infrastructure hospitals costs. As such the study depended on in-17 
kind support from the hospital, so this study was in constant competition with other better-18 
funded studies or trials. JCS also depended on good relationships and goodwill from the heads 19 
of hospital departments and associated staff. Although relationship building was successful, 20 
staff turnover meant that this was an ongoing process. Staff turnover within the study meant 21 
that skilled personnel were lost to the study and training was required once again. 22 
Although patient recruitment finished in 2016, there are still ongoing associated costs. These 23 
include the cost of long-term storage of samples, DNA extraction, ethics report-backs, data 24 
curatorship and publication expenses. However, the data and sample repository from this 25 
study remains an invaluable asset to cancer researchers, particularly given the current 26 
interest in the genetic risk factors for cancer in African ancestry patients, and efforts are being 27 
made to maintain this asset for future studies. 28 
A further challenge is that cohort studies (rather than case control) are now increasingly 29 
considered the gold standard in epidemiology. However, they are very expensive, especially 30 
if biobanking is involved, and difficult to conduct in resource constrained environments due 31 
to loss to follow up. 32 
Assuming an adult cancer incidence of 188 per 100 000, a cohort of ~584 000 adults would be 33 
needed to yield ~1100 cancer patients (recruited by the JCS annually).39 Therefore, a well-34 
designed, strictly managed case-control study was chosen to be the study design of choice in 35 
this setting.40-43 36 
 37 
Data Resource Access: 38 
Access to data from the JCS is managed through a data access agreement with the National 39 
Cancer Registry of South Africa. In brief: detailed protocols are submitted and reviewed by 40 
10 
internal/expert research committees. Data are released to the investigators once protocols 1 
are approved and ethical clearance obtained, and data transfer agreements and memoranda 2 
of understanding are signed. The JCS database contains only de-identified data linked by a 3 
study number to blood and serum samples. Ethical approval for using DNA and associated 4 
data from this repository is required for each new study. Samples and data shared with 5 
researchers external to the NCR are required to have a Material Transfer Agreement (MTA) 6 
in place. We have previously obtained ethical permission to send DNA and serum for 7 
microarray DNA analyses and multiplex serum analyses to the United Kingdom and Germany 8 
with standard MTAs from the Wits HREC. Cost-recovery principles apply. Preference is placed 9 
on proposals which promote data pooling, equal collaborative opportunities, and 10 
enhancement of research capacity in SA. Sharing of anonymised genetic data with the 11 
scientific community will be done via resources such as the European Genome-phenome 12 
Archive after approval by the Wits HREC and an approved data access committee. 13 
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Table 1. Basic demographic and lifestyle characteristics of cancer patients in the 
Johannesburg cancer study. 
 1995 – 2004  
(n=9 530)# 
2005-2016  
(n= 15 441)# 
Top three cancer types (% of total) – Males (M) Oesophagus 
(17.0%), 




Oral cavity and 
pharynx (11.3%), 
Lung (10.2%) 








Cancers histologically verified 97.4% 98.9% 
Cancers ill defined 3.0% 3.5% 
% Female 63.7% 68.4% 
Median age – years (IQR) 52 (42-62) 51 (41-60) 
Age-group:  18-24 years 
                      25-54 years 
                      55-74 years 





Urban place of birth 46.6% 49.0% 
Urban place of residence 81.7% 91.5% 
Secondary school leavers  8.1% 20.5% 
Using electricity to cook (now) 69.5% 84.2% 
Using coal + anthracite to cook (now) 11.1% 2.7% 
Using electricity for heating (now) 65.0% 65.7% 
Using coal + anthracite for heating (now) 16.8% 11.7% 
Smoker (M) – current smokersa 31.4% 30.1% 
Smoker (F) – current smokersa 5.1% 4.9% 
Median number of cigs/day (M)a 9 7 
Median number of cigs / day (F)a 5 4 
≥ Moderate alcohol drinkers (M) (>200g per week)b 39.2% 39.9% 
≥ Moderate alcohol drinkers (F) (>200g per week)b 12.5% 9.4% 
HIV positive (M)c 6.6% 15.4% 
HIV positive (F)c 8.8% 21.6% 
Currently using oral contraception only (F only 18-44 years)d 5.3% 3.3% 
Currently using injectable contraception only (F only 18-44 year)d 16.4% 19.8% 
Median age at first childbirth (15-54 years as childbearing age) 
(IQR)d 
21 (19-24) 20 (18-22) 
Median number of children (F) 3 3 
Median self-reported sexual partners 4 4 
Language Zulu  24.3% 25.3% 
Language Sesotho 19.5% 17.9% 
Language Tswana 19.1% 17.5% 
Language Xhosa 13.3% 12.1% 
Note these figures are illustrative, the percentages are calculated per each study period - comprising 
crude estimates in both potential cases and controls - see Table 2. 
#Total number of cancer patients interviewed and recruited within each study period. 
aSmoking behaviour was estimated with the exclusion of smoking-related cancers. 
bAlcohol consumption was estimated with the exclusion of alcohol-related cancers. 
cHIV prevalence was estimated in cancers unrelated to known infectious agents. 
dContraception use were estimated in female cancers unrelated to reproductive or hormonal factors. 
Table 2. Potential controls selection for cancer types in four scenarios: investigating 












hormonal factors (F) 
Anus (C21) 62/60 Case Case Control Control 
Bladder (C67) 31/79 Case Case Case Control 
Bone (C40-41) 60/100 Control Control Control Control 
Brain (C71) 29/29 Control Control Control Control 
Breast (C50)  5028/64 Control Uncleare/Control Case/Uncleare Case 
Cervix (C53) 5267/NA Case/NA Case/NA Case/NA Case 
CNS (C72) 4/3 Control Control Control Control 
Colon (C18-20)  476/518 Control Case Case Control 
Endocrine gland (C75) 23/16 Control Control Control Control 
Endometrium (C54-55)  516/NA Control/NA Control/NA Control/NA Case 
Eye and Adnexa (C69) 59/51 Case Control Control Control 
Fallopian tube (C57.0) 8/NA Control/NA Control/NA Control/NA Case 
HL (C81) 155/168 Case Control Control Control 
Kaposi Sarcoma (C46) 690/881 Case Control Control Case 
Kidney (C64) 34/44 Control Case Case Control 
Larynx (C32) 42/353 Control Case Case Control 
Leukaemia (not Myeloid) 
(C91-95) 111/135 Case Control Control Control 
Liver (C22) 78/185 Case Case Case Case 
Lung Cancer (C33-34) 266/861 Control Case Case Control 
Melanoma (C43) 67/44 Control Control Control Control 
Meninges (C70) 13/5 Control Control Control Control 
Myeloid Leukaemia  
(ICD-10 C92) 160/171 Control Case Control Control 
Myeloma (C90) 180/180 Control Control Control Control 
Nasal cavity and 
nasopharynx (C11,C30,C31) 82/147 Case Case Unclear
e Control 
NHL (C82-83) 425/494 Case Control Control Control 
Oesophagus (C15) 589/1008 Control Case Case Control 
Oral cavity and pharynx 
(C00-10, C12-14) 270/861 Case Case Case Control 
Ovaries (C56) 474/NA Control/NA Case/NA Control/NA Case 
Pancreas (C25) 95/133 Control Case Case Control 
Penis (C60) NA/49 NA/Case NA/Case NA/Control NA 
Peripheral nerves & ANS 
(C47) 2/7 Control Control Control Control 
Peritoneum and 
retroperitoneum (C48) 20/9 Control Control Control Control 
Placenta (C58.9) 77/NA Control/NA Control/NA Control/NA Unclear# 
Prostate (C61)7 NA/719 NA/Control NA/Control NA/Control NA 
Scrotum (C63.2) NA/7 NA/Control NA/Control NA/Control NA 
Small Intestine (C17) 12/11 Control Control Control Control 
Soft Tissue Sarcoma (C49) 140/148 Unclear#/Control Control Control Control 
Squamous cell carcinoma 
(C44) 78/74 Unclear
e/Case Control Control Control 
Stomach (C16) 168/256 Case Case Case Control 
Testes (C62) NA/30 NA/Control NA/Control NA/Control NA 
Thymus (C37) 5/10 Control Control Control Control 
Thyroid (C73) 55/13 Control Control Control Case 
Vagina (C52) 59/NA Case/NA Case/NA Case/NA Case 
Vulva (C51) 282/NA Case/NA Case/NA Case/NA Case 
Decision to classify cancer types is based mainly on IARC Monographs on Carcinogenicity to Humans 
and other current literature available at the time of selection.12 Cancer types with little research on 
their causality are defaulted to control status and tested using sensitivity analysis (see methods).  
NA – Not applicable for sex specific cancers.  
eLack of convincing evidence in current literature for cancer causality.  
 
Table 3. Key results arising from case-control analyses of the JCS. 
Exposure Cancer type Cases/controlsg OR (95%CI) Ref 
HIV- / KSHV high 
titre 
HIV+ / KSHV high 
titre 










Squamous cell skin 






















Anti HBc+ & 
HBV DNA+ & 
HBsAg+ 












Smoke & alcohol 
M 
F 
Lung – M 
Lung – F  
Oesophageal – M 
Oesophageal – F  
Oral – M 
Oral – F  
Laryngeal – M 
Oesophageal - M 
Oesophageal - F 



































Lung – M 
Lung – F 





























































gNumber of controls listed once. 
$Patients with unknown HIV status were excluded from the analysis. 
fTSLU=Time since last use. 
M = Male; F= Female; y=years. 
 
